12:14:11 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaFirst North Stockholm
Scandinavian Chemotech är ett forskningsbolag. Idag specialiserar sig bolaget inom kemoterapi (ECT) vid behandling utav olika cancerformer. Bolagets produkt baseras på elektrokemoterapi som skickar elektroniska impulser under behandlingen för att lättare kunna nå cellernas DNA och därmed öka möjligheten till en bättre behandling. Behandlingen kan användas för såväl hudcancer som tumörer. Huvudkontoret ligger i Lund.


2022-03-08 Bokslutskommuniké 2021
2021-11-02 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-25 Ordinarie utdelning CMOTEC B 0.00 SEK
2021-05-24 Årsstämma 2021
2021-05-04 Kvartalsrapport 2021-Q1
2021-03-08 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-20 Ordinarie utdelning CMOTEC B 0.00 SEK
2020-05-19 Årsstämma 2020
2020-05-13 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-12 Kvartalsrapport 2019-Q3
2019-08-12 Kvartalsrapport 2019-Q2
2019-05-09 Ordinarie utdelning CMOTEC B 0.00 SEK
2019-05-08 Kvartalsrapport 2019-Q1
2019-05-08 Årsstämma 2019
2019-03-19 Extra Bolagsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-15 Kvartalsrapport 2018-Q2
2018-05-15 Kvartalsrapport 2018-Q1
2018-05-15 Extra Bolagsstämma 2018
2018-03-01 Ordinarie utdelning CMOTEC B 0.00 SEK
2018-02-28 Årsstämma 2018
2018-01-30 Bokslutskommuniké 2017
2017-05-31 Extra Bolagsstämma 2017
2021-11-24 16:47:59

The Company's CEO Mohan Frick attended the physical signing ceremony and thus the official start of the Centre of Excellence collaboration, which has been initiated at India Sweden Healthcare Innovation Centre at AIIMS Jodhpur. The first TSE training treatments for breast, head and neck cancer were also performed.

Mohan Frick, our international application specialist Gayahtri Iyer and representatives from Business Sweden were present during the signing ceremony. Yesterday, the Company's applications specialist completed the training and certification of five doctors within the fields of surgery, medical oncology and radiology at AIIMS Jodhpur. These are the first doctors to be certified in TSE at a State hospital in India.

The patients, who were treated during the training, suffered from cancer where the assessment had been made that standard of care will not be beneficial. This now marks the start of the CoE that is expected to initiate its first studies with the aim of establishing clinical data for the effect of TSE treatment. The treatments performed were not part of any study.

"It has been a long process and both the Company and the doctors have been looking forward to reaching this goal for a while. Although it may now take a long time to get the go-ahead from the Ethics Committee, it feels as if we have already reached an important milestone today which in the long run can create completely new opportunities for TSE and the patients we will treat." - says Mohan Frick, CEO of ChemoTech

"We are happy to initiate the collaboration with the training on Tumour Specific Electroporation that is conducted this week. We are looking forward to conduct clinical research to evaluate the impact of this technology on the patient outcomes after it gets all the required clearances from the Ethical Committee."- says Dr. Sanjeev Misra, Director, AIIMS Jodhpur